Understanding Hepatitis B Clinical Trials:
Epidemiology, Endpoints, and Enhancing Protocols

INGENŪ CRO

Introduction

Hepatitis B (HBV) is a liver infection caused by a DNA virus from the Hepadnaviridae family.

It is a significant public health issue due to its ability to cause both acute and chronic infections, potentially leading to severe liver damage, including cirrhosis, liver failure, and hepatocellular carcinoma (HCC)—the most common form of primary liver cancer. HBV is highly contagious and spreads through blood, semen, vaginal secretions, and other bodily fluids. It is most commonly transmitted through perinatal transmission, unsafe injections, sexual contact, and injection drug use.

iNGENŪ CRO

Book a Discovery Call to learn how iNGENū can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENū CRO?

iNGENū is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENū can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Insights on Hepatitis B

Key Characteristics

HBV infection is divided into two main types:

1. **Acute Hepatitis B:** A short-term illness that occurs within six months of exposure to the virus. Many individuals clear the virus naturally without requiring specific treatment.
2. **Chronic Hepatitis B:** This occurs when the infection persists for more than six months. Chronic HBV may lead to severe liver complications, including fibrosis, cirrhosis, and HCC.

Key Characteristics

- **Asymptomatic Nature:** Many HBV infections are asymptomatic in their early stages, contributing to its unnoticed spread. Around 65-70% of acute HBV infections are asymptomatic, while most individuals with chronic HBV do not show signs until significant liver damage has occurred.
- **Chronicity and Progression:** Chronic HBV infection occurs in 5-10% of infected adults. However, in infants, around 90% of perinatally acquired infections become chronic. Chronic HBV leads to progressive liver damage, increasing the risk of cirrhosis or liver cancer in 15-40% of cases.
- **Global Distribution:** HBV is prevalent worldwide, with high endemicity in regions such as Sub-Saharan Africa and East Asia, where 5-10% of the population is chronically infected. In contrast, North America and Western Europe have lower endemicity, with rates of less than 1%.

Historical Perspectives and Evolution of Understanding

Historical Perspectives

Hepatitis B has been a known disease for centuries, with evidence of infection even in ancient human remains. However, modern understanding of HBV began in the 1960s when Dr. Baruch Blumberg discovered the Hepatitis B surface antigen (HBsAg) in the blood of an Australian aborigine. This discovery laid the foundation for the development of diagnostic tools and, eventually, the HBV vaccine, earning Blumberg the Nobel Prize in 1976.

Over the decades, understanding and managing Hepatitis B have significantly evolved. In the 1960s-1970s, the identification of HBV and its antigens enabled blood tests that became essential for screening blood donors, greatly reducing transmission risks through transfusions. The 1982 introduction of the Hepatitis B vaccine was a pivotal moment, particularly in lowering mother-to-child transmission and protecting healthcare workers at high risk. Since the 1990s, antiviral therapies like lamivudine, tenofovir, and entecavir have transformed chronic HBV treatment by effectively suppressing viral replication and reducing risks of liver damage and hepatocellular carcinoma, though a complete cure remains elusive.

Factors Contributing to Hepatitis B

Biological Factors

- HBV Genotypes
- Age and Immune Response
- Co-infections

Psychological Factors

- Anxiety and depression
- stigma associated with viral infections

Environmental Factors

- Geographic Variation
- Socioeconomic Factors
- Migration

Prevalence and Expected Trends

Prevalence of HBV

In 2019, 296 million people worldwide were living with chronic HBV, and there were 820,000 deaths annually from HBV-related complications, such as cirrhosis and liver cancer. HBV remains a leading cause of liver cancer, which accounts for 50-60% of hepatocellular carcinoma cases globally.

Trends (2013-2023):

- Decline in High-Income Countries: In the U.S., HBV incidence has dropped significantly, from 1.5 per 100,000 in 2010 to 1.0 per 100,000 in 2020, due to robust vaccination efforts.
- Global Endemicity: In Sub-Saharan Africa and East Asia, infection rates remain high at over 8% due to vertical transmission.

Future Projections (2024-2034)

Looking forward, HBV incidence and prevalence are expected to continue declining, particularly in countries with robust vaccination programs. The WHO has set ambitious goals to eliminate viral hepatitis as a public health threat by 2030, aiming for a 90% reduction in new infections and a 65% reduction in mortality.

Hepatitis B Market

Market Growth Drivers:

- **New Antiviral Drugs**: Drugs like **TAF** and **entecavir** provide better viral suppression and are safer for long-term use, especially in preventing kidney and bone toxicity.
- **Combination Therapies**: Combining antiviral agents with immune modulators, like pegylated interferon, enhances therapeutic efficacy and reduces drug resistance. This dual approach is being researched extensively to achieve a **functional cure**.

Key Drugs in the Hepatitis B Market

Drug Name	Company	Market Share	Earning Potential (USD)
Vemlidy (TAF)	Gilead Sciences	High	$862 million (2023)
Baraclude	Bristol-Myers Squibb	Moderate	$680 million (estimated)
Viread (TDF)	Gilead Sciences	Moderate	Declining; peaked at $1.2 billion
Pegasys	Roche	Moderate	$500 million (estimated)
Heplisav-B	Dynavax Technologies	Growing	$154 million (2022)

Diagnostic Criteria for Hepatitis B

ICD-11 Code for Hepatitis B

ICD-11 Code: 1E51.0 - Chronic Viral Hepatitis B without Delta-agent

- Chronic Viral Hepatitis B: This refers to long-term infection with the Hepatitis B virus (HBV), where the virus persists for more than six months. It may progress silently, with few or no symptoms even when cirrhosis develops, although clinical features can include fatigue, a hard liver edge, and complications like muscle wasting, ascites (fluid buildup in the abdomen), and splenomegaly/portal hypertension. The virus is transmitted through blood and body fluids, sexual transmission, and from mother to child at birth (vertical transmission).
- Without Delta-agent: This refers to cases of chronic Hepatitis B that are not co-infected with the Hepatitis D virus (HDV), a more severe form of hepatitis that can occur only in the presence of HBV.

For Acute Viral Hepatitis B, the ICD-11 code is slightly different:

- ICD-11 Code: 1E50 - Acute Viral Hepatitis B

Both acute and chronic forms of Hepatitis B can have significant health impacts, but chronic HBV infection is particularly concerning due to its long-term risk of liver complications.

Diagnostic Criteria for Chronic Hepatitis B

- **Serological Markers:**
  - The detection of Hepatitis B surface antigen (HBsAg) in the blood for over six months indicates chronic infection. HBsAg appears first in acute HBV infection, and its persistence signals chronicity. The presence of Hepatitis B e-antigen (HBeAg) suggests active viral replication and infectivity, though the virus can remain active even when HBeAg is absent in some chronic cases.
- **HBV DNA Testing:**
  - Quantification of HBV DNA (viral load) is critical in determining the level of viral replication and monitoring the effectiveness of antiviral therapy. A high HBV DNA level indicates active viral replication.
- **Liver Function Tests (LFTs):**
  - Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are indicative of liver inflammation, commonly seen in chronic HBV infection. Abnormal liver function tests are important in assessing liver damage.
- **Liver Histology:**
  - In cases where clinical uncertainty exists, a liver biopsy may be performed to evaluate the extent of liver damage, including inflammation and fibrosis. Chronic HBV can cause varying degrees of liver fibrosis, which can progress to cirrhosis if untreated.

Epidemiology of Hepatitis B

Global Burden of Hepatitis B:

Globally, an estimated 296 million people were living with chronic HBV infection as of 2019, according to the World Health Organization (WHO). Chronic Hepatitis B causes approximately 820,000 deaths annually due to complications such as liver cirrhosis and hepatocellular carcinoma (HCC). Despite significant progress in reducing new infections, largely through vaccination, HBV continues to pose a major health challenge in low- and middle-income countries (LMICs) where healthcare access remains limited.

Key Epidemiological Indicators:

- Prevalence of Chronic Hepatitis B: Approximately 3.9% of the global population is infected with chronic HBV.
- Acute vs. Chronic Infection: Only a small proportion of acute HBV infections progress to chronic HBV, with the progression rate being largely dependent on age.
- Mortality: HBV contributes to 50-60% of primary liver cancer cases globally, as well as a substantial portion of deaths related to liver cirrhosis.

Age Distribution and Risk Factors:

The risk of chronic HBV infection is closely linked to the age at which the virus is acquired. There is a marked difference in the likelihood of chronic infection depending on whether the infection is acquired perinatally, in early childhood, or during adulthood.

Perinatal and Early Childhood Transmission:

One of the most significant factors in the epidemiology of HBV is the high risk of chronic infection when the virus is transmitted from mother to child during childbirth (vertical transmission) or in early childhood (horizontal transmission). Studies have consistently shown that the younger the individual at the time of infection, the more likely they are to develop chronic Hepatitis B.

The high rate of chronic infection in infants and young children underscores the critical importance of neonatal vaccination programs. These initiatives have been essential in reducing the global burden of chronic HBV, particularly in countries where vertical transmission (mother-to-child transmission) is the primary mode of infection.

Epidemiology of Hepatitis B (cont.)

Middle-Aged and Older Adults:
While the majority of individuals who acquire HBV in adulthood clear the infection, the virus can still pose a significant threat to older adults, particularly in populations with risk factors such as intravenous drug use, unsafe sexual practices, or occupational exposure to blood (e.g., healthcare workers). In these populations, chronic HBV infection can lead to a higher risk of cirrhosis and liver cancer, especially in those with long-standing infections.

Racial and Ethnic Groups:
The distribution of HBV infection varies widely among racial and ethnic groups, often reflecting geographic prevalence and migration patterns.

- East Asians and Pacific Islanders: Hepatitis B is highly prevalent in East Asia and the Pacific Islands, where 5-10% of the population is chronically infected. Perinatal transmission remains a significant driver of HBV infection in these regions. In the United States, Asian Americans are disproportionately affected due to migration from HBV-endemic areas.
- Sub-Saharan Africans: HBV prevalence in Sub-Saharan Africa is similarly high, with 5-8% of the population infected. Horizontal transmission during childhood is common, often due to close contact with infected family members or unsafe medical practices.

Geographic Location:
The geographic distribution of HBV is highly variable, with high-endemic, intermediate-endemic, and low-endemic regions. The geographic location of a population plays a significant role in the prevalence of chronic Hepatitis B, largely due to differences in vaccination coverage, healthcare access, and transmission modes.

Genetic Predisposition:
While HBV infection is primarily driven by viral exposure, some studies have suggested that genetic factors may play a role in influencing the progression of HBV infection, particularly in terms of the risk of developing complications such as cirrhosis or hepatocellular carcinoma. For instance Genetic Polymorphisms and HBV Genotypes.

Socioeconomic and Behavioral Risk Factors:
In addition to biological factors, socioeconomic and behavioral factors significantly influence the epidemiology of HBV. These include: Unsafe Medical Practices, Intravenous Drug Use and Sexual Transmission.

INGENŪ CRO

Pivotal Endpoints for Hepatitis B Clinical Trials:

Key Challenges and Solutions

1. HBV DNA Suppression
2. HBeAg Seroconversion
3. HBsAg Loss
4. ALT Normalization
5. Liver Histological Improvement
6. Resistance to Antiviral Drugs
7. Virologic Response Off-treatment
8. Reduction in Liver Cancer Incidence
9. Patient-Reported Outcomes (PROs)
10. Renal and Bone Safety (Tenofovir)

INGENŪ CRO

1. Endpoint: HBV DNA Suppression

- HBV DNA suppression refers to the reduction of hepatitis B viral DNA to undetectable levels, which reduces the risk of liver damage and cirrhosis progression. Achieving sustained viral suppression is the main therapeutic goal in HBV treatment as it directly correlates with improved clinical outcomes.

Challenge:

- Maintaining long-term suppression can be difficult after stopping treatment, leading to relapse.

Solution:

- Combination therapies using antivirals with different mechanisms, like Tenofovir and Entecavir, can provide more robust suppression. Regular monitoring of viral load is essential, and for high-risk patients, long-term therapy may be necessary to prevent relapse.

2. Endpoint: HBeAg Seroconversion

- HBeAg seroconversion occurs when the hepatitis B e-antigen (HBeAg) disappears and anti-HBe antibodies appear, indicating the immune system is controlling the infection. This endpoint is an important marker of viral suppression and is associated with better long-term outcomes in chronic HBV patients.

Challenge:

- Seroconversion may not occur in all patients, especially in older adults or those with HBeAg-negative HBV.

Solution:

- Therapy can be personalized by identifying younger patients or those with high ALT levels who are more likely to achieve seroconversion. Extending treatment duration in certain patients increases the chances of seroconversion.

3. Endpoint: HBsAg Loss

- HBsAg loss represents a functional cure in Hepatitis B, where the surface antigen of the virus is cleared from the blood. This endpoint indicates that the risk of liver disease progression, including liver cancer, is significantly reduced.

Challenge:

- Achieving HBsAg loss is rare, occurring in a small percentage of patients.

Solution:

- New therapies, such as siRNA-based treatments, are being developed to specifically target HBsAg. Immune-based therapies, like therapeutic vaccines, are also promising for achieving this outcome.

4. Endpoint: ALT Normalization

- ALT (alanine aminotransferase) is a liver enzyme that indicates inflammation. Normalization of ALT levels suggests reduced liver inflammation and improved liver health.

Challenge:

- ALT levels can fluctuate during treatment, making it difficult to assess whether liver inflammation is genuinely reduced.

Solution:

- Use a combination of biomarkers, including AST and non-invasive liver imaging techniques, to gain a comprehensive understanding of liver health. Regular monitoring over time helps to identify consistent trends rather than relying on single ALT readings.

INGENŪ CRO

5. Endpoint: Liver Histological Improvement

- This endpoint measures improvements in liver tissue, such as reduced fibrosis or cirrhosis, via biopsy. Histological improvement suggests a lower risk of liver failure or cancer.

Challenge:

- Liver biopsies are invasive and not feasible for frequent monitoring.

Solution:

- Non-invasive imaging techniques like transient elastography and MRI-based elastography offer safe alternatives for assessing liver fibrosis. Additionally, serum markers like the Fibrosis-4 Index (FIB-4) and APRI (AST to Platelet Ratio Index) can provide indirect measurements of liver damage.

6. Endpoint:Resistance to Antiviral Drugs

- Drug resistance occurs when the hepatitis B virus mutates, rendering antiviral therapies less effective. This endpoint evaluates whether a drug regimen can prevent or manage resistance..

Challenge:

- Mutations in the HBV genome can lead to resistance, particularly with long-term treatment.

Solution:

- Regular genetic testing for resistance allows early detection of mutations, enabling a switch in therapy before resistance develops. Dual therapy, using drugs like Tenofovir and Lamivudine together, reduces the likelihood of resistance.

7. Endpoint: Virologic Response Off-treatment

- Virologic response off-treatment refers to the sustained suppression of HBV DNA after stopping antiviral therapy. It indicates that the patient has achieved long-term viral control without medication.

Challenge:

- Many patients relapse after discontinuing antiviral treatment, with HBV DNA levels rising again.

Solutions:

- Extending the duration of treatment, especially for those at risk of relapse, helps maintain viral suppression. Post-treatment monitoring for at least six months is essential to detect early signs of relapse and restart therapy promptly if needed.

8. Endpoint: Reduction in Liver Cancer Incidence

- This endpoint measures the reduction in the incidence of hepatocellular carcinoma (HCC), a common complication of chronic HBV. Effective HBV treatment reduces the long-term risk of liver cancer.

Challenge:

- Long-term studies are required to show that antiviral treatment can significantly reduce HCC risk.

Solution:

- Longitudinal cohort studies tracking treated patients are necessary to gather data on cancer reduction. Patients with cirrhosis or high viral loads should undergo regular HCC screening through imaging and blood tests (e.g., alpha-fetoprotein levels).

INGENŪ CRO

9. Endpoint: Patient-Reported Outcomes (PROs)

- PROs assess a patient's quality of life and symptom relief during treatment. This endpoint helps evaluate the broader impact of treatment beyond viral suppression.

Challenge:

- Patient-reported outcomes can be subjective and difficult to quantify..

Solutions:

- Use validated tools such as the Chronic Liver Disease Questionnaire (CLDQ) and the SF-36 Health Survey to systematically assess patients' physical and emotional health. Incorporating PROs into trial design ensures that patient well-being is considered alongside clinical efficacy..

10. Endpoint: Renal and Bone Safety (Tenofovir)

- This endpoint evaluates the long-term safety of Tenofovir on kidney function and bone density. Monitoring these side effects is crucial for the safe use of the drug, especially in long-term therapy.

Challenge:

- Tenofovir Disoproxil Fumarate can cause kidney toxicity and bone density loss in some patients..

Solution:

- Switching to Tenofovir Alafenamide (Vemlidy), which has a better safety profile for kidneys and bones, is recommended for high-risk patients. Regular kidney function tests and bone density scans, alongside calcium and vitamin D supplementation, help mitigate these risks.

FDA-Approved Treatments for Hepatitis B

Drug Name	Year of Approval	Class	Sponsor	Mechanism of Action	Therapeutic Effects
Tenofovir Disoproxil Fumarate (Viread)	2008	Nucleoside/Nucleotide Analog (NRTI)	Gilead Sciences	Inhibits viral reverse transcriptase	Reduces viral load and liver inflammation
Tenofovir Alafenamide (Vemlidy)	2016	Nucleoside/Nucleotide Analog (NRTI)	Gilead Sciences	More targeted form of Tenofovir, inhibits reverse transcriptase	Reduces viral load with lower kidney and bone toxicity risks
Entecavir (Baraclude)	2005	Nucleoside/Nucleotide Analog (NRTI)	Bristol-Myers Squibb	Inhibits viral DNA polymerase	Effective in reducing HBV DNA and improving liver function
Lamivudine (Epivir-HBV)	1998	Nucleoside Analog (NRTI)	GlaxoSmithKline	Inhibits viral reverse transcriptase	Suppresses viral replication, but high rates of resistance
Adefovir Dipivoxil (Hepsera)	2002	Nucleoside Analog (NRTI)	Gilead Sciences	Inhibits viral DNA polymerase	Low resistance but limited use due to kidney toxicity
Peginterferon Alfa-2a (Pegasys)	2005	Interferon	Roche	Immune modulator that enhances host antiviral response	Suppresses viral replication and boosts immune response
Interferon Alfa-2b (Intron A)	1991	Interferon	Merck	Boosts immune response to combat viral infection	Primarily used for short-term treatment in selected patients
Telbivudine (Tyzeka)	2006	Nucleoside Analog (NRTI)	Novartis	Inhibits viral DNA polymerase	Suppresses viral replication, effective in reducing HBV DNA but high resistance over time

Top 5 Most Commonly Used Drugs in the United States

Based on real-world usage data and the availability of more effective and safer options, the following drugs are the most commonly prescribed for chronic Hepatitis B in the U.S.:

1. **Tenofovir Disoproxil Fumarate (Viread)** – Due to its effectiveness and relatively low resistance, this drug is widely used.
2. **Tenofovir Alafenamide (Vemlidy)** – With a better safety profile regarding kidney and bone health, Vemlidy is increasingly prescribed.
3. **Entecavir (Baraclude)** – Known for its low resistance rates, Entecavir is often used as first-line therapy.
4. **Peginterferon Alfa-2a (Pegasys)** – Though less commonly used due to its side effects, it is still prescribed for selected patients.
5. **Lamivudine (Epivir-HBV)** – While no longer a first-line therapy due to resistance issues, Lamivudine is still used in certain settings.

While chronic Hepatitis B remains incurable, these FDA-approved drugs offer significant improvements in managing the disease, reducing viral replication, and preventing long-term complications.

Approved Product Analysis: Tenofovir Disoproxil Fumarate

14.4 Clinical Trial Results in Adults with Chronic Hepatitis B

HBeAg-Negative Chronic HBV Subjects: Trial 0102

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Chronic Hepatitis B (HBeAg-negative)	Comparison of tenofovir disoproxil fumarate 300 mg vs HEPSERA 10 mg	Knodell necroinflammatory score, HBV DNA levels, ALT levels	Baseline	N = 375 (Total), N = 250 (Tenofovir), N = 125 (HEPSERA)	Baseline characteristics: Mean Knodell necroinflammatory score: 7.8, mean plasma HBV DNA: 6.9 $\log_{10}$ copies/mL, mean serum ALT: 140 U/L. Majority were nucleoside-naive. 77% male, 25% Asian, 65% Caucasian. 17% had prior alpha-interferon therapy, 18% were nucleoside-experienced.

HBeAg-Positive Chronic HBV Subjects: Trial 0103

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Chronic Hepatitis B (HBeAg-positive)	Complete response defined as HBV DNA < 400 copies/mL (< 69 IU/mL) and Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis	Knodell necroinflammatory score, HBV DNA levels, ALT levels, Histology	48 weeks	N=266 (Total) N = 176 (Tenofovir), N = 90 (HEPSERA)	67% complete response in Tenofovir group vs. 12% in HEPSERA group. Significant improvements in histological response (74% vs. 68%), HBV DNA levels (76% vs. 13%), and ALT normalization (68% vs. 54%). HBeAg loss/seroconversion: 20%/19% (Tenofovir) vs. 16%/16% (HEPSERA).
Adults with Chronic Hepatitis B (HBeAg-negative)	Complete response defined as HBV DNA < 400 copies/mL (< 69 IU/mL) and Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell fibrosis	Knodell necroinflammatory score, HBV DNA levels, ALT levels, Histology	48 weeks	N = 250 (Tenofovir), N = 125 (HEPSERA)	71% complete response in Tenofovir group vs. 49% in HEPSERA group. Significant improvements in histological response (72% vs. 69%), HBV DNA levels (93% vs. 63%), and ALT normalization (76% vs. 77%). No HBsAg loss or seroconversion.

Approved Product Analysis: Tenofovir Disoproxil Fumarate (cont.)

Treatment Beyond 48 Weeks: Trials 0102 and 0103

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Chronic Hepatitis B (HBeAg-negative, Trial 0102)	Sustained virologic and biochemical response after open-label extension	HBV DNA levels, ALT levels, HBsAg and HBeAg seroconversion	384 weeks	N = 389 (Tenofovir), N = 196 (HEPSERA)	Tenofovir: 73% had HBV DNA < 400 copies/mL, 63% had ALT normalization. HEPSERA: 80% had HBV DNA < 400 copies/mL, 70% had ALT normalization. Minimal HBsAg loss (1%) and seroconversion in both groups.
Adults with Chronic Hepatitis B (HBeAg-positive, Trial 0103)	Sustained virologic and biochemical response after open-label extension	HBV DNA levels, ALT levels, HBsAg and HBeAg seroconversion	384 weeks	N = 389 (Tenofovir), N = 196 (HEPSERA)	Tenofovir: 49% had HBV DNA < 400 copies/mL, 42% had ALT normalization, 20% HBeAg loss, 13% HBeAg seroconversion. HEPSERA: 56% had HBV DNA < 400 copies/mL, 50% had ALT normalization, 28% HBeAg loss, 19% HBeAg seroconversion. Minimal HBsAg loss (1%) in both groups.
Adults with Chronic Hepatitis B (Trials 0102 and 0103, subgroup with biopsy data)	Histological improvement	Ishak fibrosis score (baseline, Week 48, Week 240)	240 weeks	N = 641 (Total), N = 328 (biopsy subgroup)	Histological improvement rates for those without cirrhosis: 92% (Week 48) and 95% (Week 240). For those with cirrhosis: 97% (Week 48) and 99% (Week 240).

Lamivudine-Resistant Chronic HBV Subjects: Trial 121

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Lamivudine-Resistant Chronic Hepatitis B	Safety and efficacy of tenofovir disoproxil fumarate	HBV DNA levels, ALT levels, HBeAg and HBeAg seroconversion	96 weeks	N = 141 (Tenofovir)	89% had HBV DNA < 400 copies/mL; 62% with abnormal ALT at baseline achieved ALT normalization. Among HBeAg-positive subjects, 15% had HBeAg loss, and 11% had anti-HBe seroconversion.

Chronic HBV and Decompensated Liver Disease Subjects: Trial 0108

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Chronic HBV and Decompensated Liver Disease	Safety and efficacy of tenofovir disoproxil fumarate	HBV DNA levels, ALT levels	48 weeks	N = 45 (Tenofovir)	70% achieved HBV DNA < 400 copies/mL and 46% achieved ALT normalization. Baseline: Mean Child-Pugh score: 7, mean MELD score: 12, mean HBV DNA: 5.8 $\log_{10}$ copies/mL, mean ALT: 61 U/L.

Approved Product Analysis: Tenofovir Disoproxil Fumarate (cont.)

14.5 Clinical Trial Results in Pediatric Subjects with Chronic Hepatitis B

Pediatric Subjects 12 Years to Less Than 18 Years of Age with Chronic HBV

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Pediatric subjects (12 to <18 years) with Chronic HBV (HBeAg-negative 9%, HBeAg-positive 91%)	Efficacy of tenofovir disoproxil fumarate vs. placebo	HBV DNA levels, ALT levels	72 weeks	N = 106 (52 Tenofovir, 54 Placebo)	88% of subjects on tenofovir achieved HBV DNA < 400 copies/mL compared to 0% on placebo. 74% with abnormal ALT at baseline achieved ALT normalization compared to 31% in the placebo group. One subject experienced sustained HBsAg loss and seroconversion to anti-HBs.

Pediatric Subjects 2 Years to Less Than 12 Years of Age with Chronic HBV

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Pediatric subjects (2 to <12 years) with Chronic HBV (HBeAg-positive 96%, HBeAg-negative 4%)	Efficacy of tenofovir disoproxil fumarate vs. placebo	HBV DNA levels, ALT levels, HBeAg loss, HBeAg seroconversion	48 weeks	N = 89 (60 Tenofovir, 29 Placebo)	77% of tenofovir group achieved HBV DNA < 400 copies/mL vs. 7% in placebo. ALT normalization: 66% (Tenofovir) vs. 15% (Placebo). HBeAg loss: 30% (Tenofovir) vs. 28% (Placebo). HBeAg seroconversion: 25% (Tenofovir) vs. 24% (Placebo).

Approved Product Analysis: Tenofovir Alafenamide

14.2 Clinical Trials in Adults with Chronic Hepatitis B Virus Infection and Compensated Liver Disease

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults with Chronic HBV (HBeAg-Negative, Trial 108)	Efficacy of VEMLIDY 25 mg vs. TDF 300 mg	HBV DNA levels, ALT levels	48 weeks	N = 425 (285 VEMLIDY, 140 TDF)	HBV DNA < 29 IU/mL: 94% (VEMLIDY) vs. 93% (TDF). ALT normalization (central lab): 83% (VEMLIDY) vs. 75% (TDF). ALT normalization (AASLD): 50% (VEMLIDY) vs. 32% (TDF).
Adults with Chronic HBV (HBeAg-Positive, Trial 110)	Efficacy of VEMLIDY 25 mg vs. TDF 300 mg	HBV DNA levels, ALT levels, Serology (HBeAg Loss/Seroconversion, HBsAg Loss/Seroconversion)	48 weeks	N = 873 (581 VEMLIDY, 292 TDF)	HBV DNA < 29 IU/mL: 64% (VEMLIDY) vs. 67% (TDF). ALT normalization (central lab): 72% (VEMLIDY) vs. 67% (TDF). ALT normalization (AASLD): 45% (VEMLIDY) vs. 36% (TDF). HBeAg loss/seroconversion: 14%/10% (VEMLIDY) vs. 12%/8% (TDF). HBsAg loss/seroconversion: 1%/<1% (VEMLIDY) vs. <1%/0% (TDF).

14.3 Clinical Trials in Virologically Suppressed Adults with Chronic Hepatitis B Virus Infection Who Switched to VEMLIDY

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Virologically suppressed adults with Chronic HBV (on TDF for ≥12 months with HBV DNA < 20 IU/mL at screening)	Efficacy of switching from TDF 300 mg to VEMLIDY 25 mg vs. continuing TDF	HBV DNA levels, ALT levels, HBeAg loss/seroconversion, HBsAg loss/seroconversion	48 weeks	N = 488 (243 VEMLIDY, 245 TDF)	HBV DNA ≥ 20 IU/mL: <1% (both VEMLIDY and TDF). HBV DNA < 20 IU/mL: 96% (both VEMLIDY and TDF). ALT normalization (central lab): 89% (VEMLIDY) vs. 85% (TDF). ALT normalization (AASLD): 79% (VEMLIDY) vs. 75% (TDF). HBeAg loss/seroconversion: 8%/3% (VEMLIDY) vs. 6%/0% (TDF). HBsAg loss/seroconversion: 0% (VEMLIDY) vs. 2%/0% (TDF).

Approved Product Analysis: Tenofovir Alafenamide (cont.)

14.4 Clinical Trial in Adults with Chronic Hepatitis B Virus Infection and Renal Impairment

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Virologically suppressed adults with Chronic HBV and moderate to severe renal impairment (Cohort 1: CrCl 15-59 mL/min, Cohort 2: ESRD on hemodialysis)	Efficacy and safety of switching to VEMLIDY from TDF or other antivirals	HBV DNA levels, ALT levels, HBsAg loss	24 weeks	N = 93 (78 in Cohort 1, 15 in Cohort 2)	98% achieved HBV DNA < 20 IU/mL (97% in Cohort 1, 100% in Cohort 2). ALT normalization: 97% (central lab criteria) and 95% (AASLD criteria). No HBeAg or HBsAg loss. Mean change in HBsAg level from baseline: -0.05 $\log_{10}$ IU/mL (Cohort 1) and -0.07 $\log_{10}$ IU/mL (Cohort 2).

14.5 Clinical Trial in Pediatric Subjects 12 Years of Age and Older with Chronic Hepatitis B Virus Infection

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Pediatric subjects aged 12 to <18 years (HBeAg-positive)	Efficacy of VEMLIDY vs. placebo	HBV DNA levels, ALT levels, HBsAg loss, HBeAg seroconversion	24 weeks	N = 70 (47 VEMLIDY, 23 placebo)	21% (VEMLIDY) vs. 0% (placebo) achieved HBV DNA < 20 IU/mL. Median change in HBV DNA: -5.04 $\log_{10}$ IU/mL (VEMLIDY) vs. -0.13 $\log_{10}$ IU/mL (placebo). ALT normalization (AASLD): 44% (VEMLIDY) vs. 0% (placebo). HBeAg loss: 7% (VEMLIDY) vs. 4% (placebo). No HBsAg loss or seroconversion in either group.

Approved Product Analysis: Entecavir

14.1 Outcomes at 48 Weeks

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Nucleoside-naïve subjects with chronic HBV and compensated liver disease (HBeAg-positive, Study AI463022)	Histologic improvement, virologic suppression, ALT normalization, HBeAg seroconversion	Knodell Necroinflammatory Score, Ishak Fibrosis Score, HBV DNA levels, ALT levels	48 weeks	N = 709 (354 BARACLUDE, 355 Lamivudine)	Histologic Improvement: 72% (BARACLUDE) vs. 62% (Lamivudine); HBV DNA < 300 copies/mL: 67% (BARACLUDE) vs. 36% (Lamivudine); ALT normalization: 68% (BARACLUDE) vs. 60% (Lamivudine); HBeAg seroconversion: 21% (BARACLUDE) vs. 18% (Lamivudine).
Nucleoside-naïve subjects with chronic HBV and compensated liver disease (HBeAg-negative, Study AI463027)	Histologic improvement, virologic suppression, ALT normalization	Knodell Necroinflammatory Score, Ishak Fibrosis Score, HBV DNA levels, ALT levels	48 weeks	N = 638 (325 BARACLUDE, 313 Lamivudine)	Histologic Improvement: 70% (BARACLUDE) vs. 61% (Lamivudine); HBV DNA < 300 copies/mL: 90% (BARACLUDE) vs. 72% (Lamivudine); ALT normalization: 78% (BARACLUDE) vs. 71% (Lamivudine).

Lamivudine-refractory Subjects with Compensated Liver Disease

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Lamivudine-refractory subjects with chronic HBV and compensated liver disease	Histologic improvement, virologic suppression, ALT normalization, HBeAg seroconversion	Knodell Necroinflammatory Score, Ishak Fibrosis Score, HBV DNA levels, ALT levels	48 weeks	N = 286 (124 BARACLUDE, 116 Lamivudine for histologic endpoints; 141 BARACLUDE, 145 Lamivudine for virologic endpoints)	Histologic Improvement: 55% (BARACLUDE) vs. 28% (Lamivudine). HBV DNA < 300 copies/mL: 19% (BARACLUDE) vs. 1% (Lamivudine). ALT normalization: 61% (BARACLUDE) vs. 15% (Lamivudine). HBeAg seroconversion: 8% (BARACLUDE) vs. 3% (Lamivudine).

Lamivudine-refractory Subjects with Compensated Liver Disease

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Lamivudine-refractory subjects with chronic HBV and compensated liver disease	Histologic improvement, virologic suppression, ALT normalization, HBeAg seroconversion	Knodell Necroinflammatory Score, Ishak Fibrosis Score, HBV DNA levels, ALT levels	48 weeks	N = 286 (124 BARACLUDE, 116 Lamivudine for histologic endpoints; 141 BARACLUDE, 145 Lamivudine for virologic endpoints)	Histologic Improvement: 55% (BARACLUDE) vs. 28% (Lamivudine). HBV DNA < 300 copies/mL: 19% (BARACLUDE) vs. 1% (Lamivudine). ALT normalization: 61% (BARACLUDE) vs. 15% (Lamivudine). HBeAg seroconversion: 8% (BARACLUDE) vs. 3% (Lamivudine).

Approved Product Analysis: Entecavir (cont.)

Subjects Co-infected with HIV and HBV

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
HIV/HBV co-infected subjects with lamivudine-resistant HBV (receiving HAART)	Efficacy of BARACLUDE 1 mg vs. placebo	HBV DNA levels, ALT levels	24 weeks	N = 68 (51 BARACLUDE, 17 placebo)	HBV DNA < 300 copies/mL: 6% (BARACLUDE) vs. 0% (placebo). Mean change in HBV DNA: -3.65 $\log_{10}$ copies/mL (BARACLUDE) vs. +0.11 $\log_{10}$ copies/mL (placebo). ALT normalization: 34% (BARACLUDE) vs. 8% (placebo).

14.2 Outcomes beyond 48 Weeks

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Nucleoside-naïve, HBeAg-positive subjects (Study AI463022)	Long-term virologic suppression, ALT normalization, HBeAg seroconversion	HBV DNA levels, ALT levels, HBeAg seroconversion	Up to 96 weeks	N = 407 (243 BARACLUDE, 164 Lamivudine)	At 96 weeks, HBV DNA < 300 copies/mL: 74% (BARACLUDE) vs. 37% (Lamivudine). ALT ≤ 1 X ULN: 79% (BARACLUDE) vs. 68% (Lamivudine). HBeAg seroconversion: 11% (BARACLUDE) vs. 12% (Lamivudine).
Nucleoside-naïve, HBeAg-negative subjects (Study AI463027)	Long-term virologic suppression, ALT normalization	HBV DNA levels, ALT levels	Up to 96 weeks	N = 275 (BARACLUDE), N = 245 (Lamivudine)	At 96 weeks, HBV DNA < 300 copies/mL: 64% (BARACLUDE) vs. 34% (Lamivudine). ALT ≤ 1 X ULN: 46% (BARACLUDE) vs. 34% (Lamivudine).
Lamivudine-refractory subjects (Study AI463026)	Long-term virologic suppression, ALT normalization, HBeAg seroconversion	HBV DNA levels, ALT levels, HBeAg seroconversion	Up to 96 weeks	N = 140 (77 BARACLUDE, 63 Lamivudine)	At 96 weeks, HBV DNA < 300 copies/mL: 35% (BARACLUDE) vs. 40% (Lamivudine). ALT ≤ 1 X ULN: 55% (BARACLUDE) vs. 41% (Lamivudine). HBeAg seroconversion: 26% (BARACLUDE) vs. 8% (Lamivudine).

Approved Product Analysis: Peginterferon Alfa-2a

14.4 Chronic Hepatitis B Studies 8 and 9: PEGASYS Monotherapy

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
HBeAg-positive subjects (Study 8)	Serologic, virologic, biochemical, and histologic response	HBeAg seroconversion, HBV DNA response, ALT normalization, Ishak fibrosis score, HBsAg seroconversion	48 weeks (EOT) and 72 weeks (EOF)	N = 543 (272 Lamivudine, 271 PEGASYS)	HBeAg seroconversion: 19% (Lamivudine) vs. 32% (PEGASYS). HBV DNA response: 62% (Lamivudine) vs. 32% (PEGASYS). ALT normalization: 62% (Lamivudine) vs. 41% (PEGASYS). Histologic improvement: 40% (PEGASYS). Ishak fibrosis improvement: 32% (Lamivudine) vs. 25% (PEGASYS).
HBeAg-negative subjects (Study 9)	Serologic, virologic, biochemical, and histologic response	HBeAg seroconversion, HBV DNA response, ALT normalization, Ishak fibrosis score, HBsAg seroconversion	48 weeks (EOT) and 72 weeks (EOF)	N = 358 (181 Lamivudine, 177 PEGASYS)	HBV DNA response: 85% (Lamivudine) vs. 43% (PEGASYS). ALT normalization: 73% (Lamivudine) vs. 59% (PEGASYS). Histologic improvement: 41% (Lamivudine) vs. 48% (PEGASYS). Ishak fibrosis improvement: 31% (Lamivudine) vs. 32% (PEGASYS).

Approved Product Analysis: Lamivudine (Epivir-HBV)

14.1 Adult Subjects

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Adults (16 years and older) with chronic hepatitis B virus infection (HBeAg-positive and HBV DNA positive) – U.S. Subjects	Histologic Response at Week 52 (Trial 1)	Knodell Histologic Activity Index (HAI)	52 weeks	N = 125 (EPIVIR-HBV 100 mg: n=62; Placebo: n=63)	55% of EPIVIR-HBV group showed improvement vs. 25% of placebo. 27% of EPIVIR-HBV group had no improvement vs. 59% in placebo. Missing data: 18% in EPIVIR-HBV group, 16% in placebo.
Adults (16 years and older) with chronic hepatitis B virus infection (HBeAg-positive and HBV DNA positive) – Asian Subjects	Histologic Response at Week 52 (Trial 2)	Knodell Histologic Activity Index (HAI)	52 weeks	N = 199 (EPIVIR-HBV 100 mg: n=131; Placebo: n=68)	56% of EPIVIR-HBV group showed improvement vs. 26% of placebo. 36% of EPIVIR-HBV group had no improvement vs. 62% in placebo. Missing data: 8% in EPIVIR-HBV group, 12% in placebo.
Adults (16 years and older) with chronic hepatitis B virus infection (HBeAg-positive and HBV DNA positive) – North America & Europe Subjects	Histologic Response at Week 52 (Trial 3)	Knodell Histologic Activity Index (HAI)	52 weeks	N = 164 (EPIVIR-HBV 100 mg: n=110; Placebo: n=54)	56% of EPIVIR-HBV group showed improvement vs. 26% of placebo. 25% of EPIVIR-HBV group had no improvement vs. 54% in placebo. Missing data: 19% in EPIVIR-HBV group, 20% in placebo.
Adults (16 years and older) with chronic hepatitis B virus infection (HBeAg-positive and HBV DNA positive) – U.S. Subjects	HBeAg Seroconversion at Week 52 (Trial 1)	HBeAg Seroconversion	52 weeks	N = 132 (EPIVIR-HBV 100 mg: n=63; Placebo: n=69)	17% of EPIVIR-HBV group achieved seroconversion vs. 6% of placebo.
Adults (16 years and older) with chronic hepatitis B virus infection (HBeAg-positive and HBV DNA positive) – Asian Subjects	HBeAg Seroconversion at Week 52 (Trial 2)	HBeAg Seroconversion	52 weeks	N = 210 (EPIVIR-HBV 100 mg: n=140; Placebo: n=70)	16% of EPIVIR-HBV group achieved seroconversion vs. 4% of placebo.
Adults (16 years and older) with chronic hepatitis B virus infection (HBeAg-positive and HBV DNA positive) – North America & Europe Subjects	HBeAg Seroconversion at Week 52 (Trial 3)	HBeAg Seroconversion	52 weeks	N = 161 (EPIVIR-HBV 100 mg: n=108; Placebo: n=53)	15% of EPIVIR-HBV group achieved seroconversion vs. 13% of placebo.

Approved Product Analysis: Lamivudine (Epivir-HBV) (cont.)

14.2 Pediatric Subjects

Population	Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
Pediatric patients (ages 2 to 17 years) with chronic hepatitis B virus infection	Reduction of HBV DNA and HBeAg seroconversion at Week 52	HBeAg Seroconversion, HBV DNA Assay	52 weeks	N = 286 (EPIVIR-HBV: n=191; Placebo: n=95)	23% of EPIVIR-HBV group showed reduction in HBV DNA vs. 13% of placebo. Serum ALT normalization achieved and maintained in 55% of EPIVIR-HBV group vs. 13% of placebo. Adolescents (ages 13-17) showed less evidence of treatment effect compared to younger pediatric subjects.

Analysis of Failed Hepatitis B Drug Candidates

Name of Drug	Clinical Trial Identifier	Reason for Termination / Drug Failure	Trend Analysis
ARC-520 (Arrowhead)	NCT02065336	Failed to reduce HBsAg levels significantly	RNAi therapy showed initial promise but failed to achieve sustained HBsAg reduction in humans.
Telbivudine	NCT01529255	Off-treatment durability shown was unsatisfactory	While the trial had mixed results in achieving sustained antigen loss, it provided valuable insights into long-term treatment strategies for hepatitis B. It highlighted the difficulty in achieving a functional cure and underscored the need for combination therapies to boost efficacy. These findings have informed ongoing research, particularly in combination therapies and immunomodulatory approaches.
Baracle	NCT01913431	Entecavir from Dong-A ST found to be inefficacious than Entecavir from Bristol-Myers Squibb in terms of HBV DNA reduction, rates of HBeAg seroconversion and Alanine transaminase normalization.	Bepirovirsen, when administered at 300 mg weekly for 24 weeks, led to a sustained loss of HBsAg and HBV DNA in 9–10% of participants. However, larger and longer trials were recommended to better assess the efficacy and safety profile. The results indicated that while bepirovirsen showed promise, achieving a functional cure would likely require combination therapies targeting multiple aspects of HBV replication and immune response.
Tenofovir disoproxil fumarate, clevudine	NCT00823342	Trial terminated due to safety aspects.	Clevudine was found to have potential long-term toxicity risks, which led to the decision to stop the trial prematurely. Although tenofovir demonstrated strong viral suppression, the combination therapy did not significantly enhance efficacy, and the safety profile of clevudine raised serious concerns, leading to the termination.
Adefovir dipivoxil	NCT00071201	ADV dosing using a liquid suspension is neither safe nor effective over the current strategy of adjustment of the ADV dosing interval in subjects with impaired renal function.	Results indicated that adefovir might not be the optimal choice for this patient group due to insufficient efficacy.

Common Failure Points in Hepatitis B Clinical Trials

1. Inability to Achieve HBsAg Loss:

Many trials aiming to achieve HBsAg (Hepatitis B surface antigen) loss, which is considered a functional cure, have faced significant failures. Despite promising antiviral treatments, most therapies fail to completely eliminate HBsAg in patients, as this protein remains detectable even after long-term therapy. For instance, trials involving TLR7 and TLR8 agonists failed to show significant reductions in HBsAg despite early indications of immune modulation. This highlights the challenge of clearing the virus from infected hepatocytes.

2. Immune Modulation Approaches Failing to Achieve Functional Cure:

Immune-based therapies, such as therapeutic vaccines and immunoglobulin-based treatments, have shown limited success in Hepatitis B clinical trials. For example, therapeutic vaccines aimed at boosting the immune response to control or eradicate the virus have not achieved significant viral clearance or HBsAg loss. Similarly, trials using hepatitis B immunoglobulin (HBIG) have struggled to achieve a functional cure, with minimal impact on viral persistence and antigen levels.

3. Failure of Discontinuation Strategies:

Trials investigating treatment discontinuation after long-term nucleos(t)ide analogue (NUC) therapy have often led to relapse, with patients experiencing viral reactivation. Discontinuation studies, such as the STOP-NUC trial, showed that stopping antiviral therapy frequently led to a rebound in HBV DNA levels, making it difficult to sustain a functional cure off-treatment. This highlights the challenge of achieving durable viral control without continuous treatment.

4. High Rate of Resistance Development in Early Antivirals

Early trials using Lamivudine and Adefovir faced substantial issues with the development of viral resistance. Lamivudine, in particular, showed high rates of resistance mutations after prolonged use, rendering the treatment less effective over time. These failures have prompted the shift toward more potent antiviral agents like Tenofovir and Entecavir, which are less prone to resistance.

5. Failure to Address Covalently Closed Circular DNA (cccDNA):

One of the major unique failures in Hepatitis B research is the inability to target cccDNA, a stable form of the viral genome that persists in the liver cells even after viral suppression. Despite suppressing viral replication, therapies have not been able to eliminate cccDNA, which remains the reservoir for future reactivation of the virus. This failure to target cccDNA is a key reason why a complete cure for Hepatitis B has not yet been achieved.

Safety Concerns with Current Treatments for Hepatitis B

1. Nucleoside/Nucleotide Analogs (NRTIs):

Tenofovir Disoproxil Fumarate (TDF) and Entecavir are the two most commonly used first-line treatments for HBV due to their potency in suppressing viral replication. However, they come with specific safety concerns:

- **Kidney Toxicity:** Tenofovir, particularly in its Disoproxil Fumarate form (TDF), has been associated with nephrotoxicity (kidney damage). Prolonged use can lead to reduced kidney function, which is especially concerning for patients with preexisting renal issues. Regular monitoring of kidney function is recommended during treatment.
- **Bone Mineral Density Loss:** TDF has also been linked to bone mineral density (BMD) loss, increasing the risk of osteoporosis and fractures. This is particularly worrisome for older adults or those on long-term therapy. To manage this, healthcare providers often recommend the use of Tenofovir Alafenamide (TAF), a newer formulation that offers similar efficacy but with a significantly lower impact on bone and kidney health.
- **Lactic Acidosis:** Entecavir, though generally safe, carries a risk of lactic acidosis, especially in patients with advanced liver disease. Regular liver function monitoring is necessary to catch early signs of this rare but serious condition.

2. Peginterferon Alfa-2a:

Peginterferon is another treatment option, typically used in younger patients or those without significant liver damage. Like the other interferon therapy, interferon Alfa-2b, it comes with a host of side effects that limits its use.

- **Flu-like Symptoms:** Patients commonly experience flu-like symptoms, including fever, fatigue, and muscle aches, which can severely affect quality of life.
- **Mental Health Effects:** One of the more serious side effects of Interferon-Based Therapies is its impact on mental health, potentially leading to depression, irritability, and in some cases, suicidal thoughts. These risks make peginterferon less favorable for patients with preexisting mental health conditions.
- **Autoimmune Reactions:** Interferon-Based Therapies can trigger autoimmune reactions, where the body's immune system starts attacking its tissues, causing thyroiditis or exacerbation of preexisting autoimmune conditions.

3. Emerging Therapies:

Newer therapies, including RNA interference (RNAi) drugs and immune modulators, are being explored in clinical trials. However, these approaches are still in development, and some have raised concerns about immune overreaction or insufficient long-term efficacy. For instance, trials of RNAi therapies like ARC-520 and TLR7 agonists have failed to meet primary endpoints, partly due to safety concerns related to liver toxicity and immune-mediated damage.

Standard of Care Treatment Options for Hepatitis B

Standard of Care Treatments

1. First-line Antiviral Therapy:

Nucleoside/nucleotide analogs like Tenofovir (TAF or TDF) and Entecavir are the mainstay of HBV treatment. They are highly effective in suppressing viral replication and preventing liver damage. The choice between TDF and TAF depends on the patient's renal and bone health status, while Entecavir is often preferred for those at risk of lactic acidosis.

2. Monitoring and Follow-up:

Patients on antiviral therapy require regular monitoring of HBV DNA levels to ensure that the virus remains suppressed. Additionally, liver function tests and imaging (e.g., ultrasound or transient elastography) are recommended every 6 to 12 months to monitor for liver fibrosis, cirrhosis, or early signs of liver cancer.

3. Management of Special Populations:

- **Pregnant Women**: Pregnant women with high HBV DNA levels are recommended to receive antiviral therapy, typically Tenofovir, to reduce the risk of mother-to-child transmission. Infants born to HBV-infected mothers should receive the HBV vaccine and hepatitis B immunoglobulin (HBIG) within 12 hours of birth.
- **Children:** For children with chronic HBV, TAF and Entecavir are approved treatments, but the timing of therapy depends on age and liver disease severity. Children are monitored for growth and development, particularly if they are receiving long-term antiviral therapy.

Future Directions in HBV Care

The goal of functional cure (loss of HBsAg with or without HBeAg seroconversion) remains elusive, but advances in immunotherapy and RNAi approaches may offer hope. These treatments aim to eradicate cccDNA, the viral reservoir, which current therapies cannot reach. Clinical trials are ongoing, and while safety remains a concern, these novel therapies could transform the management of HBV in the coming years. Like mentioned previously, new treatments like Bepirovirsen, an investigational antisense oligonucleotide, are being studied in Phase III trials and have shown promise in reducing HBsAg levels, potentially moving closer to a functional cure for chronic HBV.

The management of Hepatitis B has made great strides in terms of long-term viral suppression and reducing complications. However, the safety of these therapies, particularly their impact on kidneys, bones, and mental health, remains a significant consideration in choosing the appropriate treatment plan. Regular monitoring and individualized care are key to optimizing outcomes for HBV patients.

INGENŪ CRO

Enhancing Clinical Trial Protocols for Hepatitis B

Improving clinical trial protocols for Hepatitis B is pivotal to advancing our understanding and treatment. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Biomarker Use:

Incorporating biomarkers such as HBV DNA levels and serum HBsAg quantification is essential in hepatitis B trials as they provide immediate and objective measures of treatment efficacy. For example, a decline in HBV DNA levels within the first 12 weeks of treatment can indicate effective viral suppression, while a reduction in HBsAg levels can suggest immune system control over the virus. These biomarkers allow researchers to assess the success of treatments early on, facilitating quicker decision-making and potentially expediting the FDA approval process.

2. Designing Combination Trials:

Combination trials are designed to enhance efficacy by combining new therapies with standard treatments. For example, in a hepatitis B trial, researchers could combine a new TLR7 agonist with Tenofovir or Entecavir, two standard nucleotide reverse transcriptase inhibitors (NRTIs). This approach can demonstrate superior efficacy, such as greater HBV DNA suppression or HBsAg loss, compared to NRTI monotherapy alone. By showing enhanced treatment outcomes, combination trials improve the likelihood of gaining FDA approval, as they demonstrate the added benefit of the new therapy over existing treatments.

.

3. Patient Stratification:

Patient stratification in hepatitis B trials involves grouping participants based on factors like baseline viral load, liver function (e.g., ALT levels or fibrosis stage), or HBV genotype (such as genotypes A, B, C, or D). For example, patients with higher viral loads may respond differently to treatment than those with lower levels, while genotype-specific responses (e.g., genotype B patients may respond better to interferon-based therapies) allow for more targeted approaches. This stratification enhances treatment personalization, potentially improving response rates and leading to better overall trial outcomes.

Notable Key Opinion Leaders in Hepatitis B Research

Name	Specialty	Designation	Location	Brief Bio
Simone I. Strasser (MBBS, MD, FRACP, FAASLD)	Hepatology; Gastroenterology,	Clinical Associate Professor, University of Sydney	New South Wales, Australia	Associate Professor Simone Strasser is a Senior Staff Specialist in the AW Morrow Gastroenterology and Liver Centre, and the Australian National Liver Transplant Unit at Royal Prince Alfred Hospital and the University of Sydney in Sydney Australia. She is a leading figure in managing chronic liver diseases, including hepatitis B, and has been involved in several clinical trials for antiviral therapies. Dr. Strasser's research focuses on liver transplantation, liver cancer, and the clinical management of chronic viral hepatitis
Alexander J. Thompson (MBBS, PhD, FRACP)	Gastroenterology	Professor, University of Melbourne	Victoria, Australia	Dr. Thompson is a Professor of Gastroenterology at the University of Melbourne and Director of Gastroenterology at St. Vincent's Hospital. His research centers on improving treatments for chronic hepatitis B and C, with a focus on antiviral therapies and the genetic factors influencing disease progression. Dr. Thompson is a leading voice in translational research and has contributed to international hepatitis B treatment guidelines.
Stephen A. Locarnini (BSc(Hons), PhD, MBBS, FRC(Path))	Infectious Disease	Professor, Victorian Infectious Diseases Reference Laboratory	Victoria, Australia	Dr. Locarnini is the Head of Research and Molecular Development at the Victorian Infectious Diseases Reference Laboratory (VIDRL) and Director of the WHO Collaborating Centre for Virus Reference and Research. His work primarily focuses on hepatitis B, particularly in antiviral resistance and public health policy. He has received numerous accolades, such as the Malaysian Liver Foundation Medal for work on Viral Hepatitis and the EASL Award for Scientific Recognition.
Gregory J. Dore (MBBS, BSc, FRACP, MPH, PhD)	Infectious Disease; Public Health	Professor, University of New South Wales	New South Wales, Australia	Professor Gregory J. Dore is the Head of the Viral Hepatitis Clinical Research Program at the Kirby Institute, UNSW Sydney, and serves as an Infectious Diseases Physician at St. Vincent's Hospital in Sydney. With over 25 years of experience in viral hepatitis and HIV epidemiological research, clinical care, and public health policy, he is internationally recognized for his work on hepatitis C (HCV) and hepatitis B. His research focuses on HCV natural history, therapeutic strategies for treating HCV, particularly in marginalized populations, and strategies for HCV elimination. He also established St. Vincent's viral hepatitis service in 1999, which is now one of the leading treatment centers in Australia for hepatitis, focusing on vulnerable populations.
Jacob George (MBBS, FRACP, PhD, FAASLD)	Gastroenterology; Hepatology	Professor, University of Sydney	New South Wales, Australia	Professor Jacob George is currently the Professor of Hepatic Medicine at the University of Sydney and a leading hepatologist specializing in liver diseases, including hepatitis B and C. His research focuses on the development and progression of liver disease and liver cancer, particularly in viral hepatitis. He has made significant contributions to clinical trials and investigator-initiated research on viral hepatitis, liver fibrosis, and liver immunology. In the field of hepatitis B, Professor George is involved in understanding the epidemiology, prevention, and management of the disease, linking laboratory discoveries to clinical applications. His translational research has shaped modern clinical practice, especially in understanding host genetic responses to viral hepatitis infections. Professor George is an advisor to Hepatitis Australia, the Transfusion Related AIDS and Infectious Diseases Service, and at state and national levels, on viral hepatitis.

References

- Centers for Disease Control and Prevention. (n.d.). Global burden of COPD: systematic review and meta-analysis - PubMed (nih.gov). Retrieved from https://pubmed.ncbi.nlm.nih.gov
- Food and Drug Administration. (n.d.). FDA News. Retrieved from https://www.fda.gov
- Food and Drug Administration. (n.d.). FDA.gov. Retrieved from https://www.fda.gov
- NATAP. (n.d.). Hepatitis B prevalence trends. Retrieved from https://www.natap.org
- World Health Organization. (n.d.). Eliminate viral hepatitis as a public health threat by 2030. Retrieved from https://www.who.int
- Yim, H. J., & Lok, A. S. (2006). Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology, 43(2 Suppl 1), S173-S181. https://doi.org/10.1002/hep.20956.
- Clinical Trials Arena. (n.d.). Bepirovirsen and immunoglobulin therapies for hepatitis B. Retrieved from https://www.clinicaltrialsarena.com
- Dynavax Technologies. (n.d.). HEPLISAV-B. Retrieved from https://www.dynavax.com
- ENGERTIX-B | FDA. (n.d.). Engerix-B hepatitis B vaccine. Retrieved from https://www.fda.gov
- Food and Drug Administration. (2022). FDA approves expanded use of Vemlidy for pediatric patients. Retrieved from https://www.fda.gov
- Food and Drug Administration. (n.d.). FDA News. Retrieved from https://www.fda.gov
- Gilead Sciences. (n.d.). Vemlidy (Tenofovir Alafenamide, TAF) and Viread (Tenofovir Disoproxil Fumarate, TDF). Retrieved from https://www.gilead.com
- Global burden of COPD: systematic review and meta-analysis - PubMed (nih.gov). (n.d.). Retrieved from https://pubmed.ncbi.nlm.nih.gov
- Merck & Co., Inc. (n.d.). Official Site for RECOMBIVAX HB® [Hepatitis B Vaccine (Recombinant)]. Retrieved from https://www.merckvaccines.com
- NATAP. (n.d.). Hepatitis B prevalence trends. Retrieved from https://www.natap.org
- Nature. (n.d.). VIR-2218 and VIR-3434 therapies for hepatitis B. Retrieved from https://www.nature.com
- Precision Vaccinations News. (n.d.). Bepirovirsen shows potential in hepatitis B treatment. Retrieved from https://www.precisionvaccinations.com
- Research Markets. (2023). Hepatitis B treatment market analysis. Retrieved from https://www.researchmarkets.com
- Roche. (n.d.). Pegasys (Interferon alfa-2a) for hepatitis B. Retrieved from https://www.roche.com
- World Health Organization. (n.d.). ICD-11 and guidelines for chronic hepatitis B. Retrieved from https://www.who.int
- World Health Organization. (n.d.). Eliminate viral hepatitis as a public health threat by 2030. Retrieved from https://www.who.int
- Yim, H. J., & Lok, A. S. (2006). Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology, 43(2 Suppl 1), S173-S181. https://doi.org/10.1002/hep.20956
- Global burden of COPD: systematic review and meta-analysis. (n.d.). PubMed. Retrieved from https://pubmed.ncbi.nlm.nih.gov
- Lavanchy, D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis, 11(2), 97-107. https://doi.org/10.1046/j.1365-2893.2003.00487.x
- Lee, W. M., & Dienstag, J. L. (1997). Hepatitis B virus infection. New England Journal of Medicine, 337(24), 1733-1745. https://doi.org/10.1056/NEJM199712113372407
- Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J., & Bell, B. P. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology, 45(4), 529-538. https://doi.org/10.1016/j.jhep.2006.05.013
- Trépo, C., Chan, H. L. Y., & Lok, A. (2014). Hepatitis B virus infection. Lancet, 384(9959), 2053-2063. https://doi.org/10.1016/S0140-6736(14)60220-8

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.
Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com